A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
Status:
Recruiting
Trial end date:
2023-02-13
Target enrollment:
Participant gender:
Summary
This study is designed to determine the efficacy and safety of durvalumab in combination with
novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for
first-line metastatic triple negative breast cancer